TOBI® and BETHKIS® are aerosolized forms of the antibiotic tobramycin, which is used to treat people with CF who are chronically infected with Pseudomonas aeruginosa.
In the US, the FDA approved TOBI® in 1997.
In Australia,TOBI® is approved.
In the US, the TOBI® program was sponsored by Novartis Pharmaceuticals and funded by Cystic Fibrosis Foundation Therapeutics (CFFT). The program was conducted within CFFT's Therapeutics Development Network.
Contact us about Inhaled Tobramycin >